Toripalimab combined with lenvatinib

COMBINATION_PRODUCT2 trials

Sponsors

Shanghai Zhongshan Hospital, Shanghai Junshi Bioscience Co., Ltd.

Conditions

Advanced Hepatocellular Carcinoma (HCC)Cholangiocarcinoma, Intrahepatic

Phase 2

Two-cohort Study of Toripalimab(PD1)+Lenvatnib, or Gemox+Lenvatinib in Advanced Intrahepatic Cholangiocarcinoma

CompletedNCT04361331

Shanghai Zhongshan HospitalCholangiocarcinoma, Intrahepatic

Start: 2020-03-06End: 2023-09-01Updated: 2025-02-07

Phase 3

Phase III Study of Toripalimab（JS001） Combined With Lenvatinib for Advanced HCC

Active, not recruitingNCT04523493

Shanghai Junshi Bioscience Co., Ltd.Advanced Hepatocellular Carcinoma (HCC)

Start: 2020-06-29End: 2027-03-31Updated: 2026-07-06

Related Papers

Anti-PD1 antibody toripalimab combined with lenvatinib, or GEMOX chemotherapy combined with lenvatinib as first-line therapy in patients with advanced intrahepatic cholangiocarcinoma: a randomized, open, two-cohort Phase 2 Study.

2025-10-21

Safety and Efficacy of Toripalimab in Patients with Cholangiocarcinoma: An Open-Label, Phase 1 Study

Journal of Immunotherapy and Precision Oncology2025-01-141 citations

Toripalimab combined with lenvatinib and GEMOX is a promising regimen as first-line treatment for advanced intrahepatic cholangiocarcinoma: a single-center, single-arm, phase 2 study

Signal Transduction and Targeted Therapy2023-03-17132 citations

Lenvatinib plus toripalimab as first-line treatment for advanced intrahepatic cholangiocarcinoma: A single-arm, phase 2 trial.

Journal of Clinical Oncology2021-05-2013 citations

Phase II study of lenvatinib in combination with GEMOX chemotherapy for advanced intrahepatic cholangiocarcinoma.

Journal of Clinical Oncology2021-05-206 citations